1
|
Sykes DB, Martinelli MM, Negoro P, Xu S, Maxcy K, Timmer K, Viens AL, Alexander NJ, Atallah J, Snarr BD, Baistrocchi SR, Atallah NJ, Hopke A, Scherer A, Rosales I, Irimia D, Sheppard DC, Mansour MK. Transfusable neutrophil progenitors as cellular therapy for the prevention of invasive fungal infections. J Leukoc Biol 2022; 111:1133-1145. [PMID: 35355310 DOI: 10.1002/jlb.4hi1221-722r] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 03/07/2022] [Indexed: 12/19/2022] Open
Abstract
The use of mature neutrophil (granulocyte) transfusions for the treatment of neutropenic patients with invasive fungal infections (IFIs) has been the focus of multiple clinical trials. Despite these efforts, the transfusion of mature neutrophils has resulted in limited clinical benefit, likely owing to problems of insufficient numbers and the very short lifespan of these donor cells. In this report, we employed a system of conditionally immortalized murine neutrophil progenitors that are capable of continuous expansion, allowing for the generation of unlimited numbers of homogenous granulocyte-macrophage progenitors (GMPs). These GMPs were assayed in vivo to demonstrate their effect on survival in 2 models of IFI: candidemia and pulmonary aspergillosis. Mature neutrophils derived from GMPs executed all cardinal functions of neutrophils. Transfused GMPs homed to the bone marrow and spleen, where they completed normal differentiation to mature neutrophils. These neutrophils were capable of homing and extravasation in response to inflammatory stimuli using a sterile peritoneal challenge model. Furthermore, conditionally immortalized GMP transfusions significantly improved survival in models of candidemia and pulmonary aspergillosis. These data confirm the therapeutic benefit of prophylactic GMP transfusions in the setting of neutropenia and encourage development of progenitor cellular therapies for the management of fungal disease in high-risk patients.
Collapse
Affiliation(s)
- David B Sykes
- Harvard Medical School, Boston, Massachusetts, USA
- Center for Regenerative Medicine, Boston, Massachusetts, USA
- Harvard Stem Cell Institute, Boston, Massachusetts, USA
| | - Michelle M Martinelli
- Harvard Medical School, Boston, Massachusetts, USA
- Center for Regenerative Medicine, Boston, Massachusetts, USA
- Harvard Stem Cell Institute, Boston, Massachusetts, USA
| | - Paige Negoro
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Shuying Xu
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Katrina Maxcy
- Harvard Medical School, Boston, Massachusetts, USA
- Center for Regenerative Medicine, Boston, Massachusetts, USA
- Harvard Stem Cell Institute, Boston, Massachusetts, USA
| | - Kyle Timmer
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Adam L Viens
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Natalie J Alexander
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Johnny Atallah
- Harvard Medical School, Boston, Massachusetts, USA
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Brendan D Snarr
- Research Institute of the McGill University Health Center, Montreal, Canada
| | | | - Natalie J Atallah
- Harvard Medical School, Boston, Massachusetts, USA
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Alex Hopke
- BioMEMS, Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Allison Scherer
- Harvard Medical School, Boston, Massachusetts, USA
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Ivy Rosales
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Daniel Irimia
- BioMEMS, Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Donald C Sheppard
- Research Institute of the McGill University Health Center, Montreal, Canada
| | - Michael K Mansour
- Harvard Medical School, Boston, Massachusetts, USA
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
| |
Collapse
|
2
|
Barros N, Alexander N, Viens A, Timmer K, Atallah N, Knooihuizen SAI, Hopke A, Scherer A, Dagher Z, Irimia D, Mansour MK. Cytokine Augmentation Reverses Transplant Recipient Neutrophil Dysfunction against the human fungal pathogen, Candida albicans. J Infect Dis 2021; 224:894-902. [PMID: 33417688 DOI: 10.1093/infdis/jiab009] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Accepted: 01/07/2021] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Solid organ (SOT) and stem cell transplant (SCT) recipients are at increased risk of invasive fungal disease despite normal neutrophil counts. Here, we measure neutrophil anti-Candida activity. METHODS Twenty-one SOT and 19 SCT recipients were enrolled 2-4 months post-transplant and compared to 23 healthy control patients (HC). Neutrophils were co-incubated with C. albicans and percent killing, and swarming responses were measured. RESULTS Neutrophils from transplant patients had decreased fungicidal capacity compared to HC (42%, 43%, 72%; SCT, SOT, and HC respectively; SCT vs. HC p<0.0001, SOT vs. HC p<0.0001, SOT vs. SCT p=0.8) including diminished ability to control hyphal growth (HC vs SOT and HC vs. SCT, 0.1455 vs. 0.3894, p ≤0.001, 0.1455 vs. 0.6295, p ≤0.0001, respectively). Serum from SCT, but not SOT recipients, inhibited the ability of HC neutrophils to control C. albicans (37%, 45%, 55%; SCT, SOT, and HC, respectively). Neutrophils control of hyphal growth was partially restored with G-CSF or GM-CSF. CONCLUSION Despite normal circulating numbers, our data suggests that neutrophils from SOT and SCT recipients mount dysfunctional responses against C. albicans. Intrinsic neutrophil changes and extrinsic serum factors may be responsible for the dysfunction, which is partially reversed with cytokine augmentation.
Collapse
Affiliation(s)
- Nicolas Barros
- Division of Infectious Diseases, Indiana University Health, Indianapolis, IN, USA
| | - Natalie Alexander
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
| | - Adam Viens
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
| | - Kyle Timmer
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
| | - Natalie Atallah
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.,Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | | | - Alex Hopke
- Department of Surgery, Center for Engineering in Medicine, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA.,Shriners Burns Hospital Boston, MA, USA
| | - Allison Scherer
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.,Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Zeina Dagher
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.,Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Daniel Irimia
- Department of Surgery, Center for Engineering in Medicine, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA.,Shriners Burns Hospital Boston, MA, USA
| | - Michael K Mansour
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.,Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| |
Collapse
|